OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And Lipoprotein(a) Reduction to Prevent First Major Cardiovascular Events

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 11000 participants.

Also called NCT07136012

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 11,000 participants (planned count) (from the registry)
Sponsor
  • Amgen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07136012
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Australia, Canada, China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07136012. Randomized; double masking; primary purpose treatment. Start 2025-08-22 (actual); primary completion 2031-10-20 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And Lipoprotein(a) Reduction to Prevent First Major Cardiovascular Events
Condition
Cardiovascular Disease
Intervention (Drug)
Olpasiran
Intervention (Drug)
Placebo
Lead sponsor
Amgen (class: industry)

Record details

Record id
cardio:ct-nct07136012
Content hash
cc64fc60f138f15d3885be401a8fcbb0595eaf7c6440335d78b096e920f492f0